Welcome to our dedicated page for Adaptive Biotechnologies Corporation news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company dedicated to leveraging the intricate biology of the adaptive immune system to innovate in the diagnosis and treatment of diseases. The company's proprietary immune medicine platform combines high-throughput sequencing with cutting-edge computational infrastructure to offer detailed analyses of T- and B-cell repertoires, critical elements in the body's immune response. Adaptive focuses on two primary business areas: Minimal Residual Disease (MRD) and Immune Medicine.
One of Adaptive's flagship products is clonoSEQ®, a highly sensitive and standardized test authorized by the FDA for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The clonoSEQ test is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, such as diffuse large B-cell lymphoma (DLBCL). The MRD status measured by clonoSEQ serves as a powerful predictor of patient outcomes, aiding in personalized treatment and monitoring strategies.
Adaptive Biotechnologies has formed strategic partnerships with leading biopharmaceutical companies. For instance, it collaborates with Genentech on T-cell receptor (TCR) based therapeutic products, providing a neoantigen-specific T-cell receptor identified using Adaptive's TCR discovery platform. The company also signed a multi-year collaboration with BeiGene to use clonoSEQ technology in developing novel therapies for lymphoid malignancies.
In terms of financial achievements, for the year ended December 31, 2023, Adaptive reported a total revenue of $170.3 million, with the MRD revenue contributing significantly to this growth. The company achieved substantial progress in clonoSEQ test volume and introduced strategic updates to maximize the value of its MRD and Immune Medicine businesses.
Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California. Their team of world-class scientists and open, collaborative culture drive continuous innovation. The company's clinical diagnostics and pipeline developments aim to transform the clinical landscape, offering new hope for treating cancers, autoimmune disorders, and infectious diseases.
Recently, Adaptive Biotechnologies announced significant progress and strategic decisions to enhance its business operations. They integrated clonoSEQ into Epic’s specialty diagnostics suite, easing MRD monitoring accessibility for healthcare providers. The company continues to focus on driving operational efficiencies, as reflected by a decrease in operating expenses while maintaining sustainable growth.
Adaptive Biotechnologies remains committed to leveraging the adaptive immune system's potent capabilities to develop and commercialize immune-driven clinical products tailored to individual patient needs. With a robust cash position, Adaptive aims for profitability in its MRD business while making targeted investments in Immune Medicine.
Adaptive Biotechnologies (Nasdaq: ADPT) has launched immunoSEQ T-MAP COVID, a proprietary product to measure and track COVID-19 specific T-cell responses in clinical trials. Utilizing data from over 1,000 COVID-19 patients, the platform highlights that T-cell responses can persist for over 90 days post-infection, providing critical insight into immunity. The product leverages the ImmuneCODE database, developed in partnership with Microsoft, to support vaccine trials and therapeutic development, and aims to enhance next-generation vaccine design.
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced the launch of ImmuneSense Lyme™, a research study aimed at improving early detection of Lyme disease, which often goes misdiagnosed. The study targets approximately 1,000 participants in areas with high Lyme incidence. Early detection is crucial as current tests have a high false negative rate of 60-70%. The initiative employs AI to analyze immune responses, especially T cells, to enhance diagnostic accuracy. Participants can enroll via local sites or tele-health, fostering broader accessibility.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced the pricing of an underwritten public offering of 8,000,000 shares at $40.00 each, raising gross proceeds of $240 million. The offering includes 6,000,000 shares from Adaptive and 2,000,000 from a selling shareholder, with an option for underwriters to purchase an additional 1,200,000 shares. Proceeds will primarily fund TCR-Antigen Map activities, scale marketing for immunoSEQ Dx products, and support R&D efforts. The transaction is expected to close on July 20, 2020.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced a proposed underwritten public offering of 8,000,000 shares of its common stock, with 6,000,000 shares from Adaptive and 2,000,000 from a selling shareholder. The company expects to grant underwriters a 30-day option for 1,200,000 additional shares. Net proceeds will primarily fund investments in TCR-Antigen Map activities and expand marketing for immunoSEQ Dx products, while also supporting R&D initiatives. The offering is subject to market conditions, and Adaptive will not receive proceeds from the selling shareholder's shares.
Adaptive Biotechnologies (Nasdaq: ADPT) will announce its financial results for Q2 2020 on August 10, 2020, after market close. The company's conference call will start at 1:30 p.m. PT (4:30 p.m. ET). Adaptive aims to leverage the adaptive immune system to develop clinical products for diagnosing and treating diseases, including cancer and autoimmune conditions. They have two commercial products and a robust clinical pipeline to drive future growth.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced participation in two upcoming investor virtual conferences. The events include a Fireside Chat at the William Blair Virtual Growth Stock Conference on June 9 at 10 a.m. PT and a Fireside Chat at the Goldman Sachs Virtual Healthcare Conference on June 11 at 1:40 p.m. PT. Interested parties can access the live and archived webcasts on the company's website. Adaptive Biotechnologies focuses on developing clinical products utilizing the adaptive immune system for diagnosing and treating diseases.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced its participation in several upcoming investor virtual conferences. Key events include the Jefferies Virtual Healthcare Conference on June 4 at 10 a.m. PT, and the William Blair Virtual Growth Stock Conference and Goldman Sachs Virtual Healthcare Conference, both on June 11, at 10 a.m. PT and 12 p.m. PT, respectively. Interested participants can access live and archived webcasts on the company’s website. Adaptive Biotechnologies focuses on using the adaptive immune system to develop diagnostic and therapeutic products for various diseases.
Adaptive Biotechnologies (Nasdaq: ADPT) reported strong financial results for Q1 2020, with revenues reaching $20.9 million, a 65% increase year-over-year. Notably, clinical tests for clonoSEQ surged 75% to 3,518 tests. The company expanded its partnership with Microsoft to tackle COVID-19 diagnostics and formed a strategic alliance with Amgen for therapeutic antibody development. However, operating expenses rose to $55.5 million, leading to a net loss of $31.4 million. Due to COVID-19 uncertainty, the company withdrew its annual revenue guidance for 2020.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities Virtual Healthcare Conference on May 6, 2020. Management will present on May 13 at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time. A live and archived webcast of the presentation will be accessible on the company’s website. Adaptive Biotechnologies focuses on utilizing the adaptive immune system for clinical applications in diagnosing and treating diseases, with a pipeline that includes products for cancer, autoimmune diseases, and infections.
FAQ
What is the current stock price of Adaptive Biotechnologies Corporation (ADPT)?
What is the market cap of Adaptive Biotechnologies Corporation (ADPT)?
What is Adaptive Biotechnologies Corporation known for?
What is clonoSEQ?
Who are some of Adaptive Biotechnologies' key partners?
What were Adaptive Biotechnologies' financial highlights for 2023?
How does Adaptive Biotechnologies contribute to personalized medicine?
What recent strategic decisions has Adaptive Biotechnologies made?
Where are Adaptive Biotechnologies' main operations located?
What is the company culture at Adaptive Biotechnologies?
What are some key clinical applications of clonoSEQ?
What are Adaptive Biotechnologies' future goals?
